Priority Research Papers:
Genomic landscape of liposarcoma
Metrics: PDF 4472 views | HTML 4866 views | ?
Deepika Kanojia1, Yasunobu Nagata2, Manoj Garg1, Dhong Hyun Lee3, Aiko Sato2, Kenichi Yoshida2, Yusuke Sato2, Masashi Sanada2,4, Anand Mayakonda1, Christoph Bartenhagen5, Hans-Ulrich Klein5, Ngan B. Doan6, Jonathan W. Said6, S. Mohith1, Swetha Gunasekar1, Yuichi Shiraishi7, Kenichi Chiba7, Hiroko Tanaka8, Satoru Miyano7,8, Ola Myklebost9,10, Henry Yang1, Martin Dugas5, Leonardo A. Meza-Zepeda9, Allan W. Silberman11, Charles Forscher3, Jeffrey W. Tyner12, Seishi Ogawa2,* and H. Phillip Koeffler1,3,13,*
1 Cancer Science Institute of Singapore, National University of Singapore, Singapore
2 Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3 Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California, School of Medicine, Los Angeles, California, USA
4 Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan
5 Institute of Medical Informatics, University of Münster, Münster, Germany
6 Department of Pathology and Laboratory Medicine, Santa Monica-University of California-Los Angeles Medical Center, Los Angeles, California, USA
7 Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
8 Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
9 Norwegian Cancer Genomics Consortium and Department of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
10 Department of Molecular Bioscience, University of Oslo, Oslo, Norway
11 Department of Surgery, Cedars Sinai Medical Center, Division of Surgical Oncology, Los Angeles, California, USA
12 Knight Cancer Institute, Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon, USA
13 National University Cancer Institute, National University Hospital, Singapore
* These authors jointly directed this work
Deepika Kanojia, email:
Keywords: liposarcoma, exome sequencing, SNP array, intra-tumor heterogeneity, therapeutics
Received: September 07, 2015 Accepted: November 26, 2015 Published: December 04, 2015
Liposarcoma (LPS) is the most common type of soft tissue sarcoma accounting for 20% of all adult sarcomas. Due to absence of clinically effective treatment options in inoperable situations and resistance to chemotherapeutics, a critical need exists to identify novel therapeutic targets. We analyzed LPS genomic landscape using SNP arrays, whole exome sequencing and targeted exome sequencing to uncover the genomic information for development of specific anti-cancer targets. SNP array analysis indicated known amplified genes (MDM2, CDK4, HMGA2) and important novel genes (UAP1, MIR557, LAMA4, CPM, IGF2, ERBB3, IGF1R). Carboxypeptidase M (CPM), recurrently amplified gene in well-differentiated/de-differentiated LPS was noted as a putative oncogene involved in the EGFR pathway. Notable deletions were found at chromosome 1p (RUNX3, ARID1A), chromosome 11q (ATM, CHEK1) and chromosome 13q14.2 (MIR15A, MIR16-1). Significantly and recurrently mutated genes (false discovery rate < 0.05) included PLEC (27%), MXRA5 (21%), FAT3 (24%), NF1 (20%), MDC1 (10%), TP53 (7%) and CHEK2 (6%). Further, in vitro and in vivo functional studies provided evidence for the tumor suppressor role for Neurofibromin 1 (NF1) gene in different subtypes of LPS. Pathway analysis of recurrent mutations demonstrated signaling through MAPK, JAK-STAT, Wnt, ErbB, axon guidance, apoptosis, DNA damage repair and cell cycle pathways were involved in liposarcomagenesis. Interestingly, we also found mutational and copy number heterogeneity within a primary LPS tumor signifying the importance of multi-region sequencing for cancer-genome guided therapy. In summary, these findings provide insight into the genomic complexity of LPS and highlight potential druggable pathways for targeted therapeutic approach.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.